Advanced search
Publication Cover
Cancer Investigation Volume 14, 1996 - Issue 5
Submit an article Journal homepage
2
Views
2
CrossRef citations to date
0
Altmetric
Original Article

Should Cost Be Considered in the Overall Evaluation of Phase II Clinical Trials of New Antineoplastic Therapies?

Maurie Markman The Cleveland Clinic Cancer Center and Department of Hematology/Oncology The Cleveland Clinic Foundation Cleveland, Ohio, 44195
Pages 498-500 | Published online: 11 Jun 2009

References

  • Geller N. L. Design of phase I and II clinical trials in cancer: A statistician's view. Cancer Invest 1984; 2(6)483–491
  • Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–214
  • Steward W. P. Granulocyte and granulocyte-macrophage colony-stimulating factors. Lancet 1993; 342: 153–157
  • Markman M. An argument in support of cost-effectiveness analysis in oncology. J Clin Oncol 1988; 6: 937–939
  • Rowinsky E. K., Cazenave L. A., Donehower R. C. Taxol: A novel invcstigational antimicrotubule agent. J Natl Cancer Inst 1990; 82: 1247–1259
  • Rowinsky E. K., Donehower R. C., Jones R. J., Tucker R. W. Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res 1988; 48: 4093–4100
  • Einzig A. I., Wiernik P. H., Sasloff J., Runowicz C. D., Goldberg G. L. Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol 1992; 10: 1748–1753
  • McGuire W. P., Rowinsky E. K., Rosenshein N. B., Grumbine F. C., Ettinger D. S., Armstrong D. K., Donehower R. C. Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989; 111: 273–279
  • Trimble E. L., Adams J. D., Vena D., Hawkins M. J., Friedman M. A., Fisherman J. S., Christian M. C., Canetta R., Onetto N., Hayn R., Arbuck S. G. Paclitaxel for platinum-refractory ovarian cancer: Results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 1993; 11: 2405–2410
  • Levin L., Hryniuk W. M. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 1987; 5: 756–767
  • Kohn E. C., Sarosy G., Bicher A., Link C., Christian M., Steinberg S. M., Rothenberg M., Adamo D. O., Davis P., Ognibene F. P., Cunnion R. E., Reed E. Dose-intense taxol: High response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 1994; 86: 18–24
  • Link C. J., Bicher A., Kohn E. C., Christian M. C., Davis P. A., Adamo D. O., Reed E., Sarosy G. A. Flexible granulocyte colony-stimulating factor dosing in ovarian cancer patients who receive dose-intense taxol therapy. Blood 1994; 83: 1188–1192

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.